Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

So VeriSign's still-low invested capital supports its high current ROIC. On an adjusted basis, the company's ROIC was 4.4% for 2023, with a five-year average of 3.9%, according to the data provided by ...

The Manheim Used Vehicle Value Index (MUVVI) ended 2024 with a year-over-year increase for the first time since 2021; the gain of 0.4% was below the long-term average of 2.3%.Used-vehicle values ...

Even a cursory search of questions on Reddit and other social media sites will tell you how often new people arrive in Ann ...

Formula E, the all-electric single-seater motor racing series, has expanded its AI and technology partnership with Google ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

Vertex's Phase 2 study of suzetrigine met its primary endpoint, reducing pain on the NPRS by -2.02 at Week 12. Post-hoc analysis revealed variability in placebo response, highlighting trial design ...